Transcriptional changes induced by the tumor dormancy-associated microRNA-190

Transcription

Volumn 4, Issue 4, 2013, Pages 177-191

  Almog, Nava ^a   Briggs, Christine ^a   Beheshti, Afshin ^a   Ma, Lili ^a   Wilkie, Kathleen P ^a   Rietman, Edward ^a   Hlatky, Lynn ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; Microrna; Osteosarcoma; Transcriptional reprogramming; Tumor dormancy

Indexed keywords

INTERFERON; MICRORNA; MICRORNA 190; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CBL PROTEIN; CBLB PROTEIN, HUMAN; DYSTROPHIN ASSOCIATED PROTEIN; MIRN190 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SYNTROPHIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DORMANCY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; OSTEOSARCOMA; PHENOTYPE; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR DORMANCY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UPREGULATION; ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DYSTROPHIN-ASSOCIATED PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; MICRORNAS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-CBL; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 84880802129     PISSN: 21541264     EISSN: 21541272     Source Type: Journal    
DOI: 10.4161/trns.25558     Document Type: Article

References (48)

1. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427:787. PMID:14985739. http://dx.doi.org/10.1038/427787a
2. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834-46. PMID:17957189. http://dx.doi.org/10.1038/nrc2256
3. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis 2008. PMID:18563595
4. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3:505-9. PMID:9142117. http://dx.doi.org/10.1038/nm0597-505
5. Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: an update. Breast Cancer Res 2007; 9:208. PMID:17561992. http://dx.doi.org/10.1186/bcr1677
6. Gimbrone MA Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136:261-76. PMID:5043412. http://dx.doi.org/10.1084/jem.136.2.261
7. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-53. PMID:7585012. http://dx.doi.org/10.1038/nm0295-149
8. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294:139-46. PMID:20363069. http://dx.doi.org/10.1016/j.canlet.2010.03.004
9. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17:320-9. PMID:21383745. http://dx.doi.org/10.1038/nm.2328
10. Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 2003; 107:688-95. PMID:14566816. http://dx.doi.org/10.1002/ijc.11491
11. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 2011; 20:701-14. PMID:22137794. http://dx.doi.org/10.1016/j.ccr.2011.11.002
12. Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006; 20:947-9. PMID:16638967. http://dx.doi.org/10.1096/fj.05-3946fje
13. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006; 98:316-25. PMID:16507828. http://dx.doi.org/10.1093/jnci/djj068
14. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009; 69:836-44. PMID:19176381. http://dx.doi.org/10.1158/0008-5472.CAN-08-2590
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97. PMID:14744438. http://dx.doi.org/10.1016/S0092-8674(04)00045-5
16. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136:642-55. PMID:19239886. http://dx.doi.org/10.1016/j.cell.2009.01.035
17. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466:835-40. PMID:20703300. http://dx.doi.org/10.1038/nature09267
18. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11:849-64. PMID:22113163. http://dx.doi.org/10.1038/nrc3166
19. Almog N, Ma L, Schwager C, Brinkmann BG, Beheshti A, Vajkoczy P, et al. Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One 2012; 7:e44001. PMID:22952847. http://dx.doi.org/10.1371/journal.pone.0044001
20. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB, et al. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 2010; 70:7841-50. PMID:20805302. http://dx.doi.org/10.1158/0008-5472.CAN-10-0970
21. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, Schramm A, et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. Clin Cancer Res 2010; 16:2971-8. PMID:20406844. http://dx.doi.org/10.1158/1078-0432.CCR-09-3215
22. De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011; 17:7684-92. PMID:22031095. http://dx.doi.org/10.1158/1078-0432.CCR-11-0610
23. Oh S, Shin S, Janknecht R. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta 2012; 1826:1-12. PMID:22425584
24. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-85. PMID:9008168. http://dx.doi.org/10.1016/S0092-8674(00)81848-6
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50. PMID:16199517. http://dx.doi.org/10.1073/pnas.0506580102
26. Achilles EG, Fernandez A, Allred EN, Kisker O, Udagawa T, Beecken WD, et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001; 93:1075-81. PMID:11459868. http://dx.doi.org/10.1093/jnci/93.14.1075
27. Udagawa T. Tumor dormancy of primary and secondary cancers. APMIS 2008; 116:615-28. PMID:18834406. http://dx.doi.org/10.1111/j.1600-0463.2008.01077.x
28. Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002; 16:1361-70. PMID:12205027. http://dx.doi.org/10.1096/fj.01-0813com
29. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009; 4:e7850. PMID:19924232. http://dx.doi.org/10.1371/journal.pone.0007850
30. Gaedcke J, Grade M, Camps J, Søkilde R, Kaczkowski B, Schetter AJ, et al. The rectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 2012; 18:4919-30. PMID:22850566. http://dx.doi.org/10.1158/1078-0432.CCR-12-0016
31. Beezhold K, Liu J, Kan H, Meighan T, Castranova V, Shi X, et al. miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. Toxicol Sci 2011; 123:411-20. PMID:21750348. http://dx.doi.org/10.1093/toxsci/kfr188
32. Zheng H, Zeng Y, Zhang X, Chu J, Loh HH, Law PY. mu-Opioid receptor agonists differentially regulate the expression of miR-190 and NeuroD. Mol Pharmacol 2010; 77:102-9. PMID:19854889. http://dx.doi.org/10.1124/mol.109.060848
33. Zheng H, Chu J, Zeng Y, Loh HH, Law PY. Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA-190 expression. J Biol Chem 2010; 285:21994-2002. PMID:20457614. http://dx.doi.org/10.1074/jbc.M110.112607
34. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 2009; 33:698-709. PMID:19030927. http://dx.doi.org/10.1007/s00268-008-9833-0
35. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99:671-8. PMID:16924677. http://dx.doi.org/10.1002/jcb.20982
36. Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V, et al.; MPD Research Consortium. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 2007; 35:1708-18. PMID:17976522. http://dx.doi.org/10.1016/j.exphem.2007.08.020
37. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11:R27. PMID:19432961. http://dx.doi.org/10.1186/bcr2257
38. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1-12. PMID:16989803. http://dx.doi.org/10.1016/j.ydbio.2006.08.028
39. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136:586-91. PMID:19239879. http://dx.doi.org/10.1016/j.cell.2009.02.005
40. Hsu YC, Osinski J, Campbell CE, Litwack ED, Wang D, Liu S, et al. Mesenchymal nuclear factor I B regulates cell proliferation and epithelial differentiation during lung maturation. Dev Biol 2011; 354:242-52. PMID:21513708. http://dx.doi.org/10.1016/j. ydbio.2011.04.002
41. Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 2011; 25:1470-5. PMID:21764851. http://dx.doi.org/10.1101/gad.2046711
42. Stenman G, Andersson MK, Andrén Y. New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle 2010; 9:2986-95. PMID:20647765. http://dx.doi.org/10.4161/cc.9.15.12515
43. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2011; 1:519-25. PMID:22328912. http://dx.doi.org/10.1016/j.coviro.2011.10.008
44. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48. PMID:17063185. http://dx.doi.org/10.1038/nri1961
45. Smyth GK. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor 2005; Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds): 397-420.
46. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5:R80. PMID:15461798. http://dx.doi.org/10.1186/gb-2004-5-10-r80
47. Du P, Kibbe WA, Lin SM. Lumi: A pipeline for processing Illumina microarray. Bioinformatics 2008; 24:1547-8. PMID:18467348. http://dx.doi.org/10.1093/bioinformatics/btn224
48. Smid M, Dorssers LC, Jenster G. Venn Mapping: Clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatics 2003; 19:2065-71. PMID:14594711. http://dx.doi.org/10.1093/bioinformatics/btg282